Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LIVN Stock Forecast 2026-2027
$82.98
Current Price
$4.56B
Market Cap
Buy 8
Hold 2
Sell 1
Wall St Analyst Ratings
Distance to LIVN Price Targets
+14.5%
To High Target of $95.00
-2.4%
To Median Target of $81.00
-19.3%
To Low Target of $67.00
LIVN Price Momentum
-0.7%
1 Week Change
+4.5%
1 Month Change
+88.7%
1 Year Change
+34.9%
Year-to-Date Change
-2.7%
From 52W High of $85.27
+102.3%
From 52W Low of $41.01
📊 TOP ANALYST CALLS
Did LIVN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if LivaNova is one of their latest high-conviction picks.
Latest LIVN Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, LIVN has a bullish consensus with a median price target of $81.00 (ranging from $67.00 to $95.00). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $82.98, the median forecast implies a -2.4% downside. This outlook is supported by 8 Buy, 2 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LIVN Analyst Ratings
8
Buy
2
Hold
1
Sell
LIVN Price Target Range
Low
$67.00
Average
$81.00
High
$95.00
Current: $82.98
Latest LIVN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LIVN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 1, 2026 | Freedom Capital Markets | Keith Hinton | Hold | Initiates | $81.00 |
| Jun 22, 2026 | Keybanc | Overweight | Maintains | $N/A | |
| May 7, 2026 | Barclays | Equal-Weight | Maintains | $N/A | |
| May 7, 2026 | Mizuho | Outperform | Maintains | $N/A | |
| May 7, 2026 | Baird | Outperform | Maintains | $N/A | |
| Feb 27, 2026 | Barclays | Equal-Weight | Maintains | $N/A | |
| Feb 25, 2026 | Needham | Buy | Maintains | $N/A | |
| Jan 9, 2026 | Barclays | Equal-Weight | Maintains | $N/A | |
| Jan 7, 2026 | Stifel | Buy | Maintains | $N/A | |
| Dec 19, 2025 | Keybanc | Overweight | Initiates | $N/A | |
| Dec 17, 2025 | Mizuho | Outperform | Maintains | $N/A | |
| Nov 13, 2025 | Mizuho | Outperform | Maintains | $N/A | |
| Nov 13, 2025 | Baird | Outperform | Maintains | $N/A | |
| Nov 6, 2025 | Baird | Outperform | Maintains | $N/A | |
| Sep 3, 2025 | Needham | Buy | Reiterates | $N/A | |
| Aug 21, 2025 | Barclays | Equal-Weight | Maintains | $N/A | |
| May 20, 2025 | Wolfe Research | Outperform | Upgrade | $N/A | |
| May 13, 2025 | Needham | Buy | Reiterates | $N/A | |
| May 8, 2025 | Barclays | Equal-Weight | Maintains | $N/A | |
| May 8, 2025 | Baird | Outperform | Maintains | $N/A |
LivaNova PLC (LIVN) Competitors
The following stocks are similar to LivaNova based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
LivaNova PLC (LIVN) Financial Data
LivaNova PLC has a market capitalization of $4.56B with a P/E ratio of 42.1x. The company generates $1.43B in trailing twelve-month revenue with a 7.5% profit margin.
Revenue growth is +14.3% quarter-over-quarter, while maintaining an operating margin of +14.4% and return on equity of +9.5%.
Valuation Metrics
Market Cap
$4.56B
Enterprise Value
$4.34B
P/E Ratio
42.1x
PEG Ratio
-0.4x
Price/Sales
3.2x
Growth & Margins
Revenue Growth (YoY)
+14.3%
Gross Margin
+67.3%
Operating Margin
+14.4%
Net Margin
+7.5%
EPS Growth
+14.3%
Financial Health
Cash/Price Ratio
+11.8%
Current Ratio
1.3x
Debt/Equity
28.4x
ROE
+9.5%
ROA
+5.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
LivaNova PLC (LIVN) Business Model
About LivaNova PLC
What They Do
Develops medical devices for cardiac and neurological treatments.
Business Model
LivaNova generates revenue by offering innovative medical devices and therapies primarily in the fields of cardiac surgery and neuromodulation. Their product portfolio includes vagus nerve stimulation therapies for conditions like epilepsy and depression, alongside advanced solutions for cardiopulmonary procedures, serving healthcare providers and patients globally.
Additional Information
Founded through a merger in 2015, LivaNova combines expertise in neuromodulation and cardiopulmonary innovation. The company is headquartered in London and operates specialized business units worldwide, along with a digital health initiative aimed at enhancing epilepsy treatment support.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
3,300
CEO
Mr. Vladimir A. Makatsaria
Country
United Kingdom
IPO Year
2015
Website
www.livanova.comLivaNova PLC (LIVN) Latest News & Analysis
Latest News
Quick Summary
LivaNova (LIVN) has reached a 52-week high. Investors may want to examine the company's fundamentals for insights on potential future gains.
Why It Matters
LivaNova reaching a 52-week high indicates strong performance, but future gains depend on its fundamentals, influencing potential investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
LivaNova to Announce Second-Quarter 2026 Results
20 days ago
Quick Summary
LivaNova PLC (Nasdaq: LIVN) will host a conference call on Aug. 5, 2026, at 1 p.m. London time to discuss its Q2 2026 results, releasing results beforehand. Audiocast available on their website.
Why It Matters
LivaNova's upcoming earnings call could reveal key financial performance metrics, impacting stock valuation and investor sentiment, particularly in the medical technology sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
LIVN's PolySync data reports an 84.5% AHI response rate in OSA patients, enhancing findings from the OSPREY study of its aura6000 System.
Why It Matters
LIVN's high AHI response rate in OSA patients suggests strong product efficacy, potentially boosting sales and market confidence, positively impacting stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
LivaNova PLC (Nasdaq: LIVN) reported that its PolySync™ algorithm improved apnea-hypopnea index response rates to 84.5% in OSA patients using proximal hypoglossal nerve stimulation, presented at SLEEP 2026.
Why It Matters
LivaNova's data on its PolySync™ algorithm improving treatment outcomes for sleep apnea strengthens its market position and potential revenue growth, signaling a positive outlook for investors.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
LivaNova PLC elected Jette Nygaard-Andersen to its Board of Directors on June 10, enhancing governance with her medtech expertise and leadership in strategic M&A and digital innovation.
Why It Matters
Jette Nygaard-Andersen's election to LivaNova's Board enhances governance and strategic direction, potentially boosting investor confidence and influencing future growth and M&A activities.
Source: Business Wire
Market Sentiment:
Neutral
LivaNova PLC (LIVN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
1 month ago
Quick Summary
LivaNova PLC (LIVN) presented at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026, sharing insights into its business and strategies.
Why It Matters
LivaNova's presentation at a prestigious healthcare conference signals potential growth opportunities, strategic insights, and investor interest in the company's future developments.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About LIVN Stock
What is LivaNova PLC's (LIVN) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, LivaNova PLC (LIVN) has a median price target of $81.00. The highest price target is $95.00 and the lowest is $67.00.
Is LIVN stock a good investment in 2027?
According to current analyst ratings, LIVN has 8 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $82.98. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LIVN stock?
Wall Street analysts predict LIVN stock could reach $81.00 in the next 12 months. This represents a -2.4% decrease from the current price of $82.98. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is LivaNova PLC's business model?
LivaNova generates revenue by offering innovative medical devices and therapies primarily in the fields of cardiac surgery and neuromodulation. Their product portfolio includes vagus nerve stimulation therapies for conditions like epilepsy and depression, alongside advanced solutions for cardiopulmonary procedures, serving healthcare providers and patients globally.
What is the highest forecasted price for LIVN LivaNova PLC?
The highest price target for LIVN is $95.00 from at , which represents a 14.5% increase from the current price of $82.98.
What is the lowest forecasted price for LIVN LivaNova PLC?
The lowest price target for LIVN is $67.00 from at , which represents a -19.3% decrease from the current price of $82.98.
What is the overall LIVN consensus from analysts for LivaNova PLC?
The overall analyst consensus for LIVN is bullish. Out of 2 Wall Street analysts, 8 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $81.00.
How accurate are LIVN stock price projections?
Stock price projections, including those for LivaNova PLC, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 3:08 AM UTC